newsfilter
← Latest News
Business Wire·

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

GH

Blood-based test enables identification of patients eligible for targeted treatment with VEPPANU™ Approval marks Guardant's third ESR1 companion diagnostic FDA approval to help guide timely treatment